ASPCU
ASPCU
A SPAC III Acquisition Corp.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $0 | $-461.34K ▼ | $70.44K ▼ | 0% | $-0.48 ▼ | $-326.26K ▼ |
| Q3-2025 | $0 | $173.96K ▼ | $480.35K ▲ | 0% | $-0.11 ▼ | $0 ▲ |
| Q2-2025 | $0 | $267.04K ▲ | $379.94K ▼ | 0% | $0.05 ▼ | $-267.04K ▼ |
| Q1-2025 | $0 | $233.88K ▼ | $413.2K ▲ | 0% | $0.05 ▲ | $-234K ▲ |
| Q4-2024 | $0 | $540.33K | $-180K | 0% | $0 | $-540K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $871.35K ▼ | $3.94M ▼ | $535.96K ▲ | $419.76K ▼ |
| Q3-2025 | $1.06M ▼ | $63.36M ▲ | $529.57K ▲ | $975K ▼ |
| Q2-2025 | $1.07M ▼ | $62.78M ▲ | $425.04K ▲ | $1.9M ▼ |
| Q1-2025 | $1.12M ▼ | $62.25M ▲ | $278.7K ▼ | $61.97M ▲ |
| Q4-2024 | $1.6M | $62.08M | $517.33K | $61.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $70.44K ▼ | $-191.28K ▼ | $59.5M ▲ | $-59.5M ▼ | $-191.28K ▼ | $-191.28K ▼ |
| Q3-2025 | $480.35K ▲ | $-5.88K ▲ | $0 | $0 | $-5.88K ▲ | $-5.88K ▲ |
| Q2-2025 | $379.94K ▼ | $-51.1K ▲ | $0 | $0 ▲ | $-51.1K ▲ | $-51.1K ▲ |
| Q1-2025 | $413.2K ▲ | $-203.06K ▲ | $0 | $-276.22K ▼ | $-479.28K ▼ | $-203.06K ▲ |
| Q4-2024 | $-179.6K | $-354.93K | $0 | $61.95M | $1.6M | $-354.93K |
5-Year Trend Analysis
A comprehensive look at A SPAC III Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
ASPCU currently offers a clean, cash-rich, debt-free balance sheet, which is exactly what is expected from a well-structured SPAC and provides a solid financial foundation for a business combination. Its income statement benefits from interest income, demonstrating prudent cash management, while expenses are relatively contained. Looking ahead to the planned merger, the target business brings a differentiated technology platform in a niche with strong tailwinds: antimicrobial, functional, and eco-friendly textiles backed by proprietary processes and patent protection.
The most fundamental risk is the absence of an operating business at ASPCU today: there is no revenue, no positive operating cash flow, and no organic path to growth without completing a merger. Interest-driven net income can fade as cash balances decline or rates change. The merger with Bioserica introduces its own uncertainties, including deal completion risk, potential shareholder redemptions, post-merger dilution, integration and scaling challenges, and the need to prove commercial traction in a competitive and evolving textile market. In addition, negative operating and free cash flow at the SPAC level emphasize that the current structure is not self-sustaining indefinitely.
The outlook hinges almost entirely on the successful closing and execution of the Bioserica transaction. In the near term, ASPCU is likely to continue operating as a cash-consuming shell while it advances the merger process. If the deal proceeds as planned, the combined company will transition from a financial vehicle into a technology-led materials business with exposure to long-term trends in sustainability and performance textiles, but also to manufacturing, regulatory, and competitive risks typical of that industry. Overall, today’s financials mostly reflect a temporary SPAC phase; the real long-term picture will depend on how effectively the combined entity converts its innovative technology and clean starting balance sheet into stable revenues, healthy margins, and consistent cash generation.
About A SPAC III Acquisition Corp.
https://www.alpha-capital.ioA SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $0 | $-461.34K ▼ | $70.44K ▼ | 0% | $-0.48 ▼ | $-326.26K ▼ |
| Q3-2025 | $0 | $173.96K ▼ | $480.35K ▲ | 0% | $-0.11 ▼ | $0 ▲ |
| Q2-2025 | $0 | $267.04K ▲ | $379.94K ▼ | 0% | $0.05 ▼ | $-267.04K ▼ |
| Q1-2025 | $0 | $233.88K ▼ | $413.2K ▲ | 0% | $0.05 ▲ | $-234K ▲ |
| Q4-2024 | $0 | $540.33K | $-180K | 0% | $0 | $-540K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $871.35K ▼ | $3.94M ▼ | $535.96K ▲ | $419.76K ▼ |
| Q3-2025 | $1.06M ▼ | $63.36M ▲ | $529.57K ▲ | $975K ▼ |
| Q2-2025 | $1.07M ▼ | $62.78M ▲ | $425.04K ▲ | $1.9M ▼ |
| Q1-2025 | $1.12M ▼ | $62.25M ▲ | $278.7K ▼ | $61.97M ▲ |
| Q4-2024 | $1.6M | $62.08M | $517.33K | $61.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $70.44K ▼ | $-191.28K ▼ | $59.5M ▲ | $-59.5M ▼ | $-191.28K ▼ | $-191.28K ▼ |
| Q3-2025 | $480.35K ▲ | $-5.88K ▲ | $0 | $0 | $-5.88K ▲ | $-5.88K ▲ |
| Q2-2025 | $379.94K ▼ | $-51.1K ▲ | $0 | $0 ▲ | $-51.1K ▲ | $-51.1K ▲ |
| Q1-2025 | $413.2K ▲ | $-203.06K ▲ | $0 | $-276.22K ▼ | $-479.28K ▼ | $-203.06K ▲ |
| Q4-2024 | $-179.6K | $-354.93K | $0 | $61.95M | $1.6M | $-354.93K |
5-Year Trend Analysis
A comprehensive look at A SPAC III Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
ASPCU currently offers a clean, cash-rich, debt-free balance sheet, which is exactly what is expected from a well-structured SPAC and provides a solid financial foundation for a business combination. Its income statement benefits from interest income, demonstrating prudent cash management, while expenses are relatively contained. Looking ahead to the planned merger, the target business brings a differentiated technology platform in a niche with strong tailwinds: antimicrobial, functional, and eco-friendly textiles backed by proprietary processes and patent protection.
The most fundamental risk is the absence of an operating business at ASPCU today: there is no revenue, no positive operating cash flow, and no organic path to growth without completing a merger. Interest-driven net income can fade as cash balances decline or rates change. The merger with Bioserica introduces its own uncertainties, including deal completion risk, potential shareholder redemptions, post-merger dilution, integration and scaling challenges, and the need to prove commercial traction in a competitive and evolving textile market. In addition, negative operating and free cash flow at the SPAC level emphasize that the current structure is not self-sustaining indefinitely.
The outlook hinges almost entirely on the successful closing and execution of the Bioserica transaction. In the near term, ASPCU is likely to continue operating as a cash-consuming shell while it advances the merger process. If the deal proceeds as planned, the combined company will transition from a financial vehicle into a technology-led materials business with exposure to long-term trends in sustainability and performance textiles, but also to manufacturing, regulatory, and competitive risks typical of that industry. Overall, today’s financials mostly reflect a temporary SPAC phase; the real long-term picture will depend on how effectively the combined entity converts its innovative technology and clean starting balance sheet into stable revenues, healthy margins, and consistent cash generation.

CEO
Sze Wai Tsang
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-

